University of Vermont Cancer Center Member Profile
Peter Kaufman, MD
Director, UVM Cancer Center Industry Sponsored Clinical Research
Full Member
Cancer Host and Environment (CHE)
Academic Interests
Dr. Peter A. Kaufman is a Professor of Medicine at the Larner College of Medicine at UVM. He serves as the Alliance for Clinical Trials in Oncology UVM Cancer Center Institutional Principal Investigator. He is an active clinician and clinical investigator, specializing in the care and treatment of patients with breast cancer. He is a leader in both clinical and translational research. He is a full member of the UVM Cancer Center, and collaborating in or overseeing numerous research studies in breast cancer. He has several primary areas of research interest, including HER-2 (+) breast cancer, and testing for and targeting HER-2/neu therapeutically, as well as novel therapies in HR+ breast cancer. His interests also include the development of new chemotherapeutic agents and approaches for patients with other subtypes of breast cancer breast cancer, and the development of novel targeted therapies for breast cancer, and translational research focused on the biologic and molecular basis of therapies for breast cancer. He has authored and co-authored numerous peer reviewed publications, and is an author on several early pivotal clinical trials evaluating Herceptin, and other novel targeted therapeutics. He is currently the study chair of a number of international, national and regional clinical trials in breast cancer. He additionally currently serves on the Breast Cancer Committee of the NCI sponsored Alliance for Clinical Trials in Oncology.
Dr. Peter A. Kaufman is a Professor of Medicine at the Larner College of Medicine at UVM. He serves as the Alliance for Clinical Trials in Oncology UVM Cancer Center Institutional Principal Investigator. He is an active clinician and clinical investigator, specializing in the care and treatment of patients with breast cancer. He is a leader in both clinical and translational research. He is a full member of the UVM Cancer Center, and collaborating in or overseeing numerous research studies in breast cancer. He has several primary areas of research interest, including HER-2 (+) breast cancer, and testing for and targeting HER-2/neu therapeutically, as well as novel therapies in HR+ breast cancer. His interests also include the development of new chemotherapeutic agents and approaches for patients with other subtypes of breast cancer breast cancer, and the development of novel targeted therapies for breast cancer, and translational research focused on the biologic and molecular basis of therapies for breast cancer. He has authored and co-authored numerous peer reviewed publications, and is an author on several early pivotal clinical trials evaluating Herceptin, and other novel targeted therapeutics. He is currently the study chair of a number of international, national and regional clinical trials in breast cancer. He additionally currently serves on the Breast Cancer Committee of the NCI sponsored Alliance for Clinical Trials in Oncology.